Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

Hims & Hers Health, Inc. shares surged 17.5% on Wednesday, marking their best performance in a week and hitting fresh highs ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...

As the telehealth industry has grown, Hers has followed suit. It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ...